Design and Synthesis of Potent Inhibitor of Apoptosis (IAP) Proteins Antagonists Bearing an Octahydropyrrolo[1,2-a]pyrazine Scaffold as a Novel Proline Mimetic.Hashimoto, K., Saito, B., Miyamoto, N., Oguro, Y., Tomita, D., Shiokawa, Z., Asano, M., Kakei, H., Taya, N., Kawasaki, M., Sumi, H., Yabuki, M., Iwai, K., Yoshida, S., Yoshimatsu, M., Aoyama, K., Kosugi, Y., Kojima, T., Morishita, N., Dougan, D.R., Snell, G.P., Imamura, S., Ishikawa, T.
(2013) J Med Chem 56: 1228-1246
- PubMed: 23298277
- DOI: https://doi.org/10.1021/jm301674z
- Primary Citation of Related Structures:
4HY0, 4HY4, 4HY5
- PubMed Abstract:
To develop novel inhibitor of apoptosis (IAP) proteins antagonists, we designed a bicyclic octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline bioisostere. This design was based on the X-ray co-crystal structure of four N-terminal amino acid residues (AVPI) of the second mitochondria-derived activator of caspase (Smac) with the X-chromosome-linked IAP (XIAP) protein. Lead optimization of this scaffold to improve oral absorption yielded compound 45, which showed potent cellular IAP1 (cIAP1 IC(50): 1.3 nM) and XIAP (IC(50): 200 nM) inhibitory activity, in addition to potent tumor growth inhibitory activity (GI(50): 1.8 nM) in MDA-MB-231 breast cancer cells. X-ray crystallographic analysis of compound 45 bound to XIAP and to cIAP1 was achieved, revealing the various key interactions that contribute to the higher cIAPI affinity of compound 45 over XIAP. Because of its potent IAP inhibitory activities, compound 45 (T-3256336) caused tumor regression in a MDA-MB-231 tumor xenograft model (T/C: -53% at 30 mg/kg).
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.